Norovirus [strains GI.1 + GII.4] (bivalent, virus-like particle) vaccine is under clinical development by Icon Genetics and currently in Phase I for Norovirus Infections. According to GlobalData, Phase I drugs for Norovirus Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Norovirus [strains GI.1 + GII.4] (bivalent, virus-like particle) vaccine LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Norovirus [strains GI.1 + GII.4] (bivalent, virus-like particle) vaccine overview
Vaccine candidate is under development for the prevention of norovirus infections. It is a bivalent, virus like particle vaccine and is administered through intramuscular route.
Icon Genetics overview
Icon Genetics, a subsidiary of Denka Co Ltd, is a biotechnology company that offers plant engineering technologies. The company develops, manufactures and markets biopharmaceutical product candidates, engineered organisms and technology platforms for plant biotechnology and plant-based production. It also commercializes proprietary transgene operating systems suites of technologies for nuclear transformation of plants, plastid transformation and pro-viral transfection of plants. The company offers production platforms and product prototypes for various pharmaceutical, animal health and chemical biotech markets. Icon Genetics is headquartered in Halle, Germany.
For a complete picture of Norovirus [strains GI.1 + GII.4] (bivalent, virus-like particle) vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
